CHILDRENS CANCER GROUP

密歇根大学卫生系统的儿科血液肿瘤科在儿童癌症小组的所有公开研究中进行合作，目的是改善癌症儿童的护理和生存。该部门是密歇根大学综合癌症中心的成员，该中心是美国国家癌症研究所指定的综合性癌症中心，是密歇根州的两个综合癌症中心之一，拥有八名全职临床研究人员，他们在密歇根大学医学院任教，还有一个已获批准的儿科血液肿瘤学奖学金项目，每三年有两名研究员接受培训。此外，如果CCG研究活动通过与密歇根州人口较多地区的五个附属机构(两个在底特律地区，一个在大急流地区，一个在东兰辛，一个在卡拉马祖)合作来加强参与。对于密歇根大学CCG网络，从1996年6月1日到1997年5月31日的12个月期间，治疗性研究的患者注册人数为121人，而生物学和非治疗性研究的注册人数为81人。在同一时期，在密歇根大学CCG网络机构进行随访的患者数量为791人。在最近的18个月期间(1995年12月1日至1997年5月31日)，密歇根大学CCG网络在35个机构的治疗性研究条目中排名第四，在生物学研究条目中排名第四，在其他研究条目中排名第五，在后续研究的总患者中排名第四，在总体数据质量方面排名第四。密歇根大学是CCG批准参与第一阶段研究的17家机构之一，也是CCG批准的骨髓移植中心。共有22名多学科调查人员被任命为科学、纪律和研究委员会以及战略小组的成员。未来，密歇根大学的这些研究人员将继续为CCG治疗、流行病学和多种恶性疾病的生物学研究做出贡献。预计在I期临床试验和骨髓移植领域将有更多的贡献。最后，该大学儿科血液学-肿瘤学的研究人员目前正在为白血病、神经母细胞瘤和脑肿瘤的分子生物学做出贡献；这些研究最终将扩展到CCG的临床试验，以评估这些发现的临床相关性和预后重要性。

The Division of Pediatric Hematology-Oncology at the University of Michigan Health System collaborates in all open studies of the Children's Cancer Group, with the goal of improving the care and survival of children with cancer. The Division is a member of the University of Michigan Comprehensive Cancer Center, an N.C.I.-designated comprehensive cancer center, one of two in the State of Michigan, and has eight full-time clinical investigators with faculty appointments at the University of Michigan Medical School, as well as an approved fellowship program in pediatric hematology-oncology with two fellows in training for each of three years. In addition, participation if CCG research activities is enhanced through collaboration with five affiliate institutions located in the more populous regions of Michigan (two in the Detroit area, one in Grand Rapids, one in East Lansing, and one in Kalamazoo). For the University of Michigan CCG Network, patient registrations on therapeutic studies numbered 121 for the 12-month period from June 1, 1996 through May 31, 1997, while entries on biology and non-therapeutic studies numbered 81. During the same time period, patients in follow-up at institutions of the University of Michigan CCG Network numbered 791. During a recent 18-month period (12/1/95 through 5/31/97), The University of Michigan CCG Network was ranked fourth among 35 institutions for therapeutic study entries, fourth for biology study entries, fifth for entries on other studies, fourth for total patients on study in follow-up, and fourth for overall data quality. The University of Michigan is one of 17 CCG institutions approved for participation in phase I studies and is a CCG-approved bone marrow transplant center. A total of 22 multidisciplinary investigators have appointments to scientific, discipline, and study committees and to strategy groups. In the future, these investigators at the University of Michigan will continue to contribute to CCG therapeutic, epidemiology, and biology research for a wide range of malignant diseases. Additional contributions can be expected in the areas of phase I clinical trials and bone marrow transplantation. Finally, investigators in Pediatric Hematology-Oncology at the University are currently making contributions to the molecular biology of leukemia, neuroblastoma and brain tumors; these studies will eventually be expanded to clinical trials in CCG in order to evaluate the clinical relevance and the prognostic importance of the findings.